Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Latest Developments in Specialty Pharma India’s pharmaceutical industry has built a global reputation as a leading supplier of affordable generic medicines. Over the past two decades, Indian com...
Key Highlights: Implications: Rubicon is using the Arinna deal to buy its way into India’s fast‑growing CNS and neuro‑psychiatry market with an immediately revenue‑accretive, chr...
